BiotechTube

IMC-A12 (cixutumumab) + IMC-A12 (cixutumumab) + IMC-A12 (cixutumumab) + IMC-A12 (cixutumumab) + IMC-A12 (cixutumumab)

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Ewing's Sarcoma /Peripheral Neuroectodermal Tumor (PNET)

Conditions

Ewing's Sarcoma /Peripheral Neuroectodermal Tumor (PNET), Rhabdomyosarcoma, Leiomyosarcoma, Adipocytic Sarcoma, Synovial Sarcoma

Trial Timeline

Jul 1, 2008 → Feb 1, 2012

NCT ID
NCT00668148

About IMC-A12 (cixutumumab) + IMC-A12 (cixutumumab) + IMC-A12 (cixutumumab) + IMC-A12 (cixutumumab) + IMC-A12 (cixutumumab)

IMC-A12 (cixutumumab) + IMC-A12 (cixutumumab) + IMC-A12 (cixutumumab) + IMC-A12 (cixutumumab) + IMC-A12 (cixutumumab) is a phase 2 stage product being developed by Eli Lilly for Ewing's Sarcoma /Peripheral Neuroectodermal Tumor (PNET). The current trial status is completed. This product is registered under clinical trial identifier NCT00668148. Target conditions include Ewing's Sarcoma /Peripheral Neuroectodermal Tumor (PNET), Rhabdomyosarcoma, Leiomyosarcoma.

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00668148Phase 2Completed

Competing Products

3 competing products in Ewing's Sarcoma /Peripheral Neuroectodermal Tumor (PNET)

See all competitors
ProductCompanyStageHype Score
CP-751,871PfizerPhase 1
29
CP-751,871PfizerPhase 1/2
32
plerixafor + plerixafor + plerixaforSanofiPhase 1/2
32